Abstract
Prosaposin, a 66 kDa glycoprotein, was identified initially as the precursor of the sphingolipid activator proteins, saposins A-D, which are required for the enzymatic hydrolysis of certain sphingolipids by lysosomal hydrolases. While mature saposins are distributed to lysosomes, prosaposin exists in secretory body fluids and plasma membranes. In addition to its role as the precursor, prosaposin shows a variety of neurotrophic and myelinotrophic activities through a receptor- mediated mechanism. In studies in vivo, prosaposin was demonstrated to exert a variety of neuro-efficacies capable of preventing neuro-degeneration following neuro-injury and promoting the amelioration of allodynia and hyperalgesia in pain models. Collective findings indicate that prosaposin is not a simple house-keeping precursor protein; instead, it is a protein essentially required for the development and maintenance of the central and peripheral nervous systems. Accumulating evidence over the last decade has attracted interests in exploring and developing new therapeutic approaches using prosaposin for human disorders associated with neuro-degeneration. In this review we detail the structure characteristics, cell biological feature, in vivo efficacy, and neuro-therapeutic potential of prosaposin, thereby providing future prospective in clinical application of this multifunctional protein.
Central Nervous System Agents in Medicinal Chemistry
Title: Biochemistry and Neurobiology of Prosaposin: A Potential Therapeutic Neuro-Effector
Volume: 9 Issue: 2
Author(s): Roberta Misasi, Isao Hozumi, Takashi Inuzuka, Antonella Capozzi, Vincenzo Mattei, Yukako Kuramoto, Hiroshi Shimeno, Shinji Soeda, Norihiro Azuma, Toyoaki Yamauchi and Masao Hiraiwa
Affiliation:
Abstract: Prosaposin, a 66 kDa glycoprotein, was identified initially as the precursor of the sphingolipid activator proteins, saposins A-D, which are required for the enzymatic hydrolysis of certain sphingolipids by lysosomal hydrolases. While mature saposins are distributed to lysosomes, prosaposin exists in secretory body fluids and plasma membranes. In addition to its role as the precursor, prosaposin shows a variety of neurotrophic and myelinotrophic activities through a receptor- mediated mechanism. In studies in vivo, prosaposin was demonstrated to exert a variety of neuro-efficacies capable of preventing neuro-degeneration following neuro-injury and promoting the amelioration of allodynia and hyperalgesia in pain models. Collective findings indicate that prosaposin is not a simple house-keeping precursor protein; instead, it is a protein essentially required for the development and maintenance of the central and peripheral nervous systems. Accumulating evidence over the last decade has attracted interests in exploring and developing new therapeutic approaches using prosaposin for human disorders associated with neuro-degeneration. In this review we detail the structure characteristics, cell biological feature, in vivo efficacy, and neuro-therapeutic potential of prosaposin, thereby providing future prospective in clinical application of this multifunctional protein.
Export Options
About this article
Cite this article as:
Misasi Roberta, Hozumi Isao, Inuzuka Takashi, Capozzi Antonella, Mattei Vincenzo, Kuramoto Yukako, Shimeno Hiroshi, Soeda Shinji, Azuma Norihiro, Yamauchi Toyoaki and Hiraiwa Masao, Biochemistry and Neurobiology of Prosaposin: A Potential Therapeutic Neuro-Effector, Central Nervous System Agents in Medicinal Chemistry 2009; 9 (2) . https://dx.doi.org/10.2174/187152409788452045
DOI https://dx.doi.org/10.2174/187152409788452045 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alzheimer’s Disease and Molecular Chaperones: Current Knowledge and the Future of Chaperonotherapy
Current Pharmaceutical Design Computer Aided Drug Design Studies in the Discovery of Secondary Metabolites Targeted Against Age-Related Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Cancer Stem Cells and the Biology of Brain Tumors
Current Stem Cell Research & Therapy The Cannabinoid CB2 Receptor as a Target for Inflammation-Dependent Neurodegeneration
Current Neuropharmacology Epigenetic and Disease Targets by Polyphenols
Current Pharmaceutical Design Dysfunction of Endoplasmic Reticulum (ER) and Mitochondria (MT) in Alzheimer's Disease: The Role of the ER-MT Cross-Talk
Current Alzheimer Research Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions
Current Drug Targets [177Lu]-DOTA0-Tyr3-Octreotate: A Potential Targeted Radiotherapeutic for the Treatment of Medulloblastoma
Current Radiopharmaceuticals Subcellular Trafficking in Rhabdovirus Infection and Immune Evasion: A Novel Target for Therapeutics
Infectious Disorders - Drug Targets Cerebral Arachidonate Cascade in Dementia: Alzheimers Disease and Vascular Dementia
Current Neuropharmacology Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease
Current Medicinal Chemistry Protein Aggregation and Defective RNA Metabolism as Mechanisms for Motor Neuron Damage
CNS & Neurological Disorders - Drug Targets Heme Oxygenase: A Target Gene for Anti-Diabetic and Obesity
Current Pharmaceutical Design Advances in Lentiviral Vectors: A Patent Review
Recent Patents on DNA & Gene Sequences Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets Phytochemicals and Cancer Stem Cells: A Pancreatic Cancer Overview
Current Chemical Biology Malaria and artemisinin derivatives: an updated review
Mini-Reviews in Medicinal Chemistry Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Current Drug Targets The Role of Nitric Oxide Synthase Inhibitors in Schizophrenia
Current Medicinal Chemistry Plant Glycosides and Aglycones Displaying Antiproliferative and Antitumour Activities – A Review
Current Bioactive Compounds